Substantiation of the model of pricing for essential drugs in the context of the Health Technology Assessments

V. M. Nazarkina

Abstract


The problem of availability of drugs can be solved by implementation of effective social and economic mechanisms.

Aim. To substantiate theoretically the effective management model of pricing for drugs.

Materials and methods. The analysis of drug availability has been conducted; the model of pharmaceutical pricing has been proposed.

Results and discussion. The effective social pricing model for drugs has been proposed. This model is based on the use of a consolidated list of essential drugs, the method of forming the cost of drugs, scientifically based methods of the state regulation of prices and the results of the Health Technology Assessments .

Conclusions. Implementation of effective social pricing model allows improving drug availability and pharmaceutical care for the population.


Keywords


pricing; essential drugs; National list of drugs; Health Technology Assessments

Full Text:

PDF

References


Intersectoral Governance for Health in All Policies Structures, actions and experiences [Електронний ресурс] / D. V. McQueen, M. Wismar, L. Vivian et al. // WHO, European Observatory on Health Systems and Policies. – 2012. – Режим доступу : http://www.euro.who.int/__data/assets/pdf_file/0005/171707/Intersectoral–governance–for–health–in–all–policies.pdf.

Немченко, А. С. Ціноутворення на лікарські засоби / А. С. Немченко, К. Л. Косяченко, О. А. Немченко. – Х. : Авіста–ВЛТ, 2012. – 304 с.

Немченко, А. С. Обґрунтування пріоритетних напрямків удосконалення ціноутворення на лікарські засоби / А. С. Немченко, В. М. Назаркіна // Укр. вісник психоневрол. – 2015. – № 3. – С. 118–122.

Danzon, P. M. Pharmaceutical Price Regulation: National Policies Versus Global Interests [Електронний ресурс] / P. M. Danzon // The AEI Press. – 2010. – Режим доступу : https://www.aei.org/wp–content/uploads/2014/07/–pharmaceutical–price–regulation–global–interests_11361924090.pdf.

Carone, G. European Economy. Cost–containment policies in public pharmaceutical spending in the EU [Електронний ресурс] / G. Carone, C. Schwierz, A. Xavier // European Commission. Economic Papers 461. – 2012. – Режим доступу : http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf

Essential Medicines Are More Available than Other Medicines around the Globe [Електронний ресурс] / Y. T. Bazargani, M. Ewen, A. de Boer et al. // PLOS. – 2014. – Режим доступу : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087576

Ruggeri, K. Pharmaceutical pricing. The use of external reference pricing / K. Ruggeri, E. Nolte. –Cambridge, 2013. – 61 p.

Pinson, N. Health Technology Assessment / N. Pinson, A. Thielke, V. King. –Portland, 2011. – 146 p.

Исследования сравнительной эффективности / Д. Ю. Белоусов, А. С. Колбин, А. А. Курылев, А. В. Павлыш // Качественная клин. практика. – 2013. – № 1. – С. 70–77.

Kosyachenko, K. L. Methodological approaches to development of the national guidelines of the health technology assessment / K. L. Kosyachenko, A. S. Nemchenko // Вісник фармації. – 2014. – № 1. – С. 54–57.

Оценка медицинских технологий и формирование политики здравоохранения в странах Европы: Современное состояние, проблемы и перспективы [Електронний ресурс] // ВОЗ, Европейская Обсерватория по системам и политике здравоохранения. – 2010. – Режим доступу : http://www.euro.who.int/__data/assets/pdf_file/0005/128525/e91922R.pdf.


GOST Style Citations


1.  McQueen, D. V., Wismar, M., Vivian, L. (2012). Intersectoral Governance for Health in All Policies Structures, actions and experiences. WHO, European Observatory on Health Systems and Policies. Available at: http://www.euro.who.int/__data/assets/pdf_file/0005/171707/Intersectoral–governance–for–health–in–all–policies.pdf.

2.  Nemchenko, A. S., Kosiachenko, K. L., Nemchenko, O. A. (2012). Tsinoutvorennia na likarski zasoby. [The pricing of medicines]. Kharkiv: Avista–VLT, 304.

3.  Nemchenko, A. S. (2015). Ukrainskii visnyk psyhonevrologii – Ukrainian journal of Psychoneurology,3, 118–122.

4.  Danzon, P. M. (2010). Pharmaceutical Price Regulation: National Policies Versus Global Interests. The AEI Press. Available at: https://www.aei.org/wp–content/uploads/2014/07/–pharmaceutical–price–regulation–global–interests_11361924090.pdf.

5.  Carone, G., Schwierz, C., Xavier, A. (2012). European Economy. Cost–containment policies in public pharmaceutical spending in the EU. European Commission. Economic Papers 461. Available at: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf

6.  Bazargani, Y. T., Ewen, M., de Boer, A. (2014). Essential Medicines Are More Available than Other Medicines around the Globe. PLOS. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087576

7.  Ruggeri, K., Nolte, E. (2013). Pharmaceutical pricing. The use of external reference pricing.Cambridge, 61.

8.  Pinson, N., Thielke, A., King, V. (2011). Health Technology Assessment. Portland, 146.

9.  Belousov, D. Yu., Korbin, A. S., Kurylev, A. A., Pavlysh, A. V. (2013). Kachestvennaia klinicheskaia practika – Good clinical practice, 1, 70–77.

10.       Kosyachenko, K. L., Nemchenko, A. S. (2014). Methodological approaches to development of the national guidelines of the health technology assessment. Visnyk farmatsiiNews of Pharmacy, 1, 54–57.

11.       Otcenka meditcinskikh tekhnologii i formirovanie politiki zdravookhraneniia v stranakh Evropy: Sovremennoe sostoianie, problemy i perspektivy. (2010). VOZ, Evropeiskaia Observatoriia po sistemam i politike zdravookhraneniia. Available at: http://www.euro.who.int/__data/assets/pdf_file/0005/128525/e91922R.pdf. 





DOI: https://doi.org/10.24959/nphj.17.2139

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)